Zoledronic acid in the management of metastatic bone disease

Bibliography

• MERCADANTE S: Malignant bone pain: pathophysiology and treatment. Pain (1997) 69:1-18.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE: Skeletal complications of malignancy. Cancer (1997) 80(Suppl. 8):1588-1594.
   PubMed Web of Science ®Google Scholar
• SHINODA H, ADAMEK G, FELIX R et al.: Structure–activity relationship of various bisphosphonates. Calcif. Tissue Int. (1983) 35:87-99.
   PubMed Web of Science ®Google Scholar
• WIDLER R, JAEGGI KA, GLATT M et al.: Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. (2002) 45(17):3721-3738.
   PubMed Web of Science ®Google Scholar
• SCHENK R, EGGLI P, FLEISCH H, ROSINI S: Quantitative morphometric evaluation of the inhibitory activity of new amino-bisphosphonates on bone resorption in the rat. Calcif. Tissue Int. (1986) 38:342-349.
   PubMed Web of Science ®Google Scholar
• SIETSEMA WK, EBETINO FH, SALVAGNO AM, BEVAN JA: Antiresorptive dose–response relationship across three generations of bisphosphonates. Drugs Exp. Clin. Res. (1989) 15:389-396.
   PubMedGoogle Scholar
• GREEN JR, MULLER K, JAEGGI KA: Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. (1994) 9:745-751.
   PubMed Web of Science ®Google Scholar
• RACKOFF PJ, SEBBA A: Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis. Treat. Endocrinol. (2005) 4(4):245-251.
   PubMedGoogle Scholar
• CRANNEY A, ADACHI JD: Corticosteroid-induced osteoporosis: a guide to optimum management. Treat. Endocrinol. (2002) 1(5):271-279.
   PubMedGoogle Scholar
• REID IR, MILLER P, LYLES K et al.: Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med. (2005) 353(9):898-908.
   PubMed Web of Science ®Google Scholar
• FLEISCH H: Bisphosphonates. Pharmacology and use in the treatment of tumor-induced hypercalcemic and metastatic bone disease. Drugs (1991) 42:919-944.
   PubMed Web of Science ®Google Scholar
• MCCLOSKEY EV, MACLENNAN CM, DRAYSON MT et al.: A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br. J. Haematol. (1998) 100:317-325.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. (1996) 335:1785-1791.
   PubMed Web of Science ®Google Scholar
• ROGERS MJ, BROWN RJ, HODKIN V et al.: Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem. Biophys. Res. Commun. (1996) 224:863-869.
   PubMed Web of Science ®Google Scholar
• ROGERS MJ, JI X, RUSSELL RG et al.: Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem. J. (1994) 303:303-311.
   PubMed Web of Science ®Google Scholar
• VAN BEEK E, PIETERMAN E, COHEN L et al.: Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. (1999) 264:108-111.
   PubMed Web of Science ®Google Scholar
• ZHANG FL, CASEY PJ: Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. (1996) 65:241-269.
   PubMed Web of Science ®Google Scholar
• VAN BEEK E, LOWIK C, VAN DER PLUIJM G, PAPAPOULOS S: The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J. Bone Miner. Res. (1999) 14:722-729.
   PubMed Web of Science ®Google Scholar
• SATO M, GRASSER W: Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J. Bone Miner. Res. (1990) 5:31-40.
   PubMed Web of Science ®Google Scholar
• DE LIBERO G: Sentinel function of broadly reactive human γδ T cells. Immunol. Today (1997) 18:22-26.
   PubMedGoogle Scholar
• FISCH P, MALKOVSKY M, KOVATS S et al.: Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt’s lymphoma cells. Science (1990) 250:1269-1273.
   PubMed Web of Science ®Google Scholar
• BUKOWSKI JF, MORITA CT, TANAKA Y et al.: Vγ9/Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer. J. Immunol. (1995) 154:998-1006.
   PubMed Web of Science ®Google Scholar
• KUNZMANN V, BAUER E, FEURLE J et al.: Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood (2000) 96:384-392.
   PubMed Web of Science ®Google Scholar
• KUNZMANN V, BAUER E, WILHELM M: γδ T cell stimulation by pamidronate. N. Engl. J. Med. (1999) 340:737-738.
   PubMed Web of Science ®Google Scholar
• GOBER HJ, KISTOWSKA M, ANGMAN L, JENO P, MORI L, DE LIBERO G: Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. (2003) 197(2):163-168.
   PubMed Web of Science ®Google Scholar
• WILHELM M, KUNZMANN V, ECKSTEIN S et al.: Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood (2003) 102(1):200-206.
   PubMed Web of Science ®Google Scholar
• SANTINI D, VESPASIANI GENTILUCCI U, VINCENZI B et al.: The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann. Oncol. (2003) 14:1468-1476.
   PubMed Web of Science ®Google Scholar
• JOHNSON JR, WILLIAMS G, PAZDUR R: End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol. (2003) 21:1404-1411.
   PubMed Web of Science ®Google Scholar
• WILLIAMS G, PAZDUR R, TEMPLE R: Assessing tumor-related signs and symptoms to support cancer drug approval. J. Biopharm. Stat. (2004) 14:5-21.
   PubMedGoogle Scholar
• MAJOR PP, COOK RJ, CHEN BL et al.: Survival-adjusted cumulative event analysis of skeletal-related events in patients with cancer metastatic to bone in trials of zoledronic acid. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzerland (24 – 26 March 2004).
   Google Scholar
• ANDERSEN PK, GILL RD: Cox’s regression model for counting processes: a large sample study. Ann. Stat. (1982) 10:1100-1120.
   Web of Science ®Google Scholar
• MAJOR P, LORTHOLARY A, HON J et al.: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. (2001) 19:558-567.
   PubMed Web of Science ®Google Scholar
• BODY JJ: Hypercalcemia of malignancy. Semin. Nephrol. (2004) 24(1):48-54.
   PubMed Web of Science ®Google Scholar
• BELCH AR, BERGSAGEL DE, WILSON K et al.: Effect of daily etidronate on the osteolysis of multiple myeloma. J. Clin. Oncol. (1991) 9:1397-1402.
   PubMed Web of Science ®Google Scholar
• DARAGON A, HUMEZ C, MICHOT C et al.: Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study. Eur. J. Med. (1993) 2:449-452.
   PubMedGoogle Scholar
• DJULBEGOVIC B, WHEATLEY K, ROSS J et al.: Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. (2002) 3:CD003188.
   PubMedGoogle Scholar
• BERENSON JR, ROSEN LS, HOWELL A et al.: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer (2001) 91:1191-1200.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, KAMINSKI M et al.: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer J. (2001) 7:377-387.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, KAMINSKI M et al.: Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer (2003) 98:1735-1744.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS M, BERENSON J, SHIRINA N, CHEN YM: Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 18S(Suppl.):7505.
   Google Scholar
• HILLNER BE, INGLE JN, CHLEBOWSKI RT et al.: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J. Clin. Oncol. (2003) 21(21):4042-4057.
   PubMed Web of Science ®Google Scholar
• COLEMAN RE: Bisphosphonates in breast cancer. Ann. Oncol. (2005) 16(5):687-695.
   PubMed Web of Science ®Google Scholar
• PATERSON AH, POWLES TJ, KANIS JA et al.: Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J. Clin. Oncol. (1993) 11:59-65.
   PubMed Web of Science ®Google Scholar
• KRISTENSEN B, EJLERTSEN B, GROENVOLD M et al.: Oral clodronate in breast cancer patients with bone metastases: a randomized study. J. Intern. Med. (1999) 246:67-74.
   PubMed Web of Science ®Google Scholar
• TUBIANA-HULIN M, BEUZEBOC P, MAURIAC L et al.: Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases. Bull. Cancer (2001) 88:701-707.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, THERIAULT RL, LIPTON A et al.: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. (1998) 16:2038-2044.
   PubMed Web of Science ®Google Scholar
• THERIAULT RL, LIPTON A, HORTOBAGYI GN et al.: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. (1999) 17:846-854.
   PubMed Web of Science ®Google Scholar
• LIPTON A, THERIAULT RL, HORTOBAGYI GN et al.: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer (2000) 88:1082-1090.
   PubMed Web of Science ®Google Scholar
• HULTBORN R, GUNDERSEN S, RYDEN S et al.: Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res. (1999) 19:3383-3392.
   PubMed Web of Science ®Google Scholar
• CONTE PF, LATREILLE J, MAURIAC L et al.: Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. J. Clin. Oncol. (1996) 14:2552-2559.
   PubMed Web of Science ®Google Scholar
• BODY JJ, DIEL IJ, LICHINITSER MR et al.: Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. (2003) 14:1399-1405.
   PubMed Web of Science ®Google Scholar
• BODY JJ, DIEL IJ, LICHINITZER M et al.: Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled Phase III studies. Br. J. Cancer (2004) 90:1133-1137.
   PubMed Web of Science ®Google Scholar
• KOHNO N, AOGI K, MINAMI H et al.: A randomized, double-blind, placebo-controlled Phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer. Proc. Am. Soc. Clin. Oncol. (2004) 23:43.
   Google Scholar
• MAJOR PP, COOK RJ, CHEN BL, ZHENG N: Multiple event analysis of zoledronic acid trials in patients with cancer metastatic to bone. Proc. Am. Soc. Clin. Oncol. (2003) 22:762 (Abstract 3062).
   Web of Science ®Google Scholar
• ROSEN LS, GORDON DH, DUGAN W JR et al.: Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer (2004) 100:36-43.
   PubMed Web of Science ®Google Scholar
• CARAGLIA M, SANTINI D, MARRA M, VINCENZI B, TONINI G, BUDILLON A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr. Relat. Cancer (2006) 13(1):7-26.
   PubMed Web of Science ®Google Scholar
• CLEMONS MJ, DRANITSARIS G, OOI WS et al.: Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J. Clin. Oncol. (2006) 24(30):4895-4900.
   PubMed Web of Science ®Google Scholar
• GARNERO P, BUCHS N, ZEKRI J, RIZZOLI R, COLEMAN RE, DELMAS PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer (2000) 82:858-864.
   PubMed Web of Science ®Google Scholar
• BROWN JE, NEVILLE-WEBBE H, COLEMAN R: The role of bisphosphonates in breast and prostate cancers. Endocr. Relat. Cancer (2004) 11:207-224
   PubMed Web of Science ®Google Scholar
• SMITH JA: Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J. Urol. (1989) 141:85-87.
   PubMed Web of Science ®Google Scholar
• ELOMAA I, KYLMALA T, TAMMELA T et al.: Effect of oral clodronate on bone pain. A controlled study in patients with metastatic prostate cancer. Int. Urol. Nephrol. (1992) 24:159-166.
   PubMed Web of Science ®Google Scholar
• KYLMALA T, TAMMELA TL, LINDHOLM TS, SEPPANEN J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Gynaecol. (1994) 83:316-319.
   PubMedGoogle Scholar
• KYLMALA T, TAUBE T, TAMMELA TL, RISTELI L, RISTELI J, ELOMA A: Concomitant i.v. and oral clodronate in the relief of bone pain - a double-blind placebo-controlled study in patients with prostate cancer. Br. J. Cancer (1997) 76:939-942.
   PubMed Web of Science ®Google Scholar
• STRANG P, NILSSON S, BRANDSTEDT S et al.: The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. (1997) 17:4717-4721.
   PubMed Web of Science ®Google Scholar
• ERNST DS, TANNOCK IF, VENNER PM et al.: Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study. Proc. Am. Soc. Clin. Oncol. (2002) 21:705.
   Google Scholar
• DEARNALEY D, SYDES MR, MASON MD et al.: A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial). J. Natl Cancer Inst. (2003) 95:1300-1311.
   PubMed Web of Science ®Google Scholar
• LIPTON A, SMALL E, SAAD F et al.: The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. (2002) 20(Suppl. 2):45-54.
   PubMed Web of Science ®Google Scholar
• SAAD F, GLEASON DM, MURRAY R et al.: Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: a randomized, placebo-controlled trial. J. Natl. Cancer Inst. (2002) 94:1458-1468.
   PubMed Web of Science ®Google Scholar
• COLEMAN R, ROSEN L, GLEASON DM et al.: Zoledronic acid has broad long-term efficacy in reducing skeletal complications in patients with bone metastases from breast cancer, prostate cancer, and other solid tumours. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzerland (24 – 26 March 2004).
   Google Scholar
• SAAD F, GLEASON D, MURRAY R et al.: Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Presented at: XIXth Congress of the European Association of Urology. Vienna, Austria (24 – 27 March 2004).
   Google Scholar
• SAAD F, GLEASON D, MURRAY R et al.: Zoledronic acid is well tolerated for up to 24 months and significantly reduces skeletal complications in patients with advanced prostate cancer metastatic to bone. J. Urol. (2003) 169:394.
   Google Scholar
• WEINFURT KP, LI Y, CASTEL LD et al.: The impact of skeletal related events on health-related quality of life of patients with metastatic prostate cancer. Ann. Oncol. (2002) 13(Suppl. 5):180.
   Google Scholar
• ROSEN LS, GORDON D, TCHEKMEDYIAN NS et al.: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer (2004) 100:2613-2621.
   PubMed Web of Science ®Google Scholar
• LIPTON A, SEAMAN J, ZHENG M: Long-term efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What is new in bisphosphonates? Seventh workshop on bisphosphonates. From the laboratory to the patient. Davos, Switzerland (24 – 26 March 2004).
   Google Scholar
• COLEMAN RE: Bisphosphonates: clinical experience. Oncologist (2004) 9(Suppl. 4):14-27.
   PubMed Web of Science ®Google Scholar
• BODY JJ, LICHINITSER M, TJULANDIN S et al.: Oral ibandronate and intravenous zoledronic acid in metastatic breast cancer patients: comparative bone turnover marker and safety data. Bone (2006) 38(Suppl. 1):S69.
   Web of Science ®Google Scholar
• RIVKIN S: Oral ibandronate versus intravenous zoledronic acid for breast cancer patients with skeletal complications: the SWOG trial. Bone (2006) 38(Suppl. 1):S82.
   Web of Science ®Google Scholar
• BARRETT-LEE P, MURRAY N: Zoledronic acid versus ibandronate comparative evaluation in breast cancer patients with bone metastases: the NCRI ZICE trial. Bone (2006) 38(Suppl. 1):S57.
   Google Scholar
• CAMERON D, FALLON M, DIEL I: Ibandronate: its role in metastatic breast cancer. Oncologist (2006) 11(Suppl. 1):27-33.
   PubMed Web of Science ®Google Scholar
• ABRAHAMSEN B, TENG AY: Technology evaluation: denosumab, Amgen. Curr. Opin. Mol. Ther. (2005) 7(6):604-10
   PubMed Web of Science ®Google Scholar
• LIPTON A, ALVARADO C, DE BOER R et al.: Randomized, active-controlled study of denosumab (AMG 162) in breast cancer patients with bone metastases not previously treated with intravenous (IV) bisphosphonates (BP). ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18S):512.
   Google Scholar
• SUAREZ T, FIZAZI K, RAHIM Y et al.: A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption. ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. (2006) 24(18S):8562.
   Google Scholar
• BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J. Clin. Oncol. (2002) 20:3719-3736.
   PubMed Web of Science ®Google Scholar
• HILLNER BE, INGLE JN, BERENSON JR et al.: American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J. Clin. Oncol. (2000) 18:1378-1391.
   PubMed Web of Science ®Google Scholar
• BERENSON JR: Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist (2005) 10:52-62.
   PubMed Web of Science ®Google Scholar
• COSTA L, DEMERS LM, GOUVEIA-OLIVEIRA A et al.: Prospective evaluation of the peptide-bound collagen Type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J. Clin. Oncol. (2002) 20:850-856.
   PubMed Web of Science ®Google Scholar
• BROWN J, COOK R, COLEMAN RE et al.: The role of bone turnover markers in predicting clinical events in metastatic bone disease. Proc. Am. Soc. Clin. Oncol. (2003) 22:738.
   Google Scholar
• MAXWELL C, SWIFT R, GOODE M, DOANE L, ROGERS M: Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid. Clin. J. Oncol. Nurs. (2003) 7(4):403-408.
   PubMedGoogle Scholar
• ZOJER N, KECK AV, PECHERSTORFER M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf. (1999) 21:389-406.
   PubMed Web of Science ®Google Scholar
• MUNNS CF, RAUCH F, MIER RJ, GLORIEUX FH: Respiratory distress with pamidronate treatment in infants with severe osteogenesis imperfecta. Bone (2004) 35(1):231-234.
   PubMed Web of Science ®Google Scholar
• PECHERSTORFER M, JILCH R, SAUTY A et al.: Effect of first treatment with aminobisphosphonates pamidronate and ibandronate on circulating lymphocyte subpopulations. J. Bone Miner. Res. (2000) 15(1):147-154.
   PubMed Web of Science ®Google Scholar
• BANERJEE D, ASIF A, STRIKER L et al.: Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am. J. Kidney Dis. (2003) 41(5):E18.
   PubMed Web of Science ®Google Scholar
• CHANG JT, GREEN L, BEITZ J: Renal failure with the use of zoledronic acid. N. Engl. J. Med. (2003) 349(17):1676-1679.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, TCHEKMEDYIAN S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial. J. Clin. Oncol. (2003) 21(16):3150-3157.
   PubMed Web of Science ®Google Scholar
• MAZJ S, LICHTMAN SM: Renal dysfunction associated with bisphosphonate use: retrospective analysis of 293 patients with respect to age and other clinical characteristics. Proc. Am. Soc. Clin. Oncol. (2004) 23:735a.
   Google Scholar
• GUARNERI V, DONATI S, NICOLINI M, CONTE P: Renal safety of zoledronic acid in patients with bone metastases from breast cancer or other tumors treated with intravenous bisphosphonates for up to ten years. Ann. Oncol. (2004) 15(Suppl. 3):811p.
   Google Scholar
• KYLE RA: Update on the treatment of multiple myeloma. Oncologist (2001) 6:119-124.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ GS, FINE PL, STACK JI et al.: Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. (2003) 64(1):281-289.
   PubMed Web of Science ®Google Scholar
• WOO SB, HELLSTEIN JW, KALMAR JR: Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann. Intern. Med. (2006) 144(10):753-761.
   PubMed Web of Science ®Google Scholar
• MAEREVOET M, MARTIN C, DUCK L: Osteonecrosis of the jaw and bisphosphonates. N. Engl. J. Med. (2005) 353(1):99-102.
   PubMed Web of Science ®Google Scholar
• BAGAN JV, MURILLO J, JIMENEZ Y et al.: Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J. Oral. Pathol. Med. (2005) 34(2):120-123.
   PubMed Web of Science ®Google Scholar
• CARTER GD, GOSS AN: Bisphosphonates and avascular necrosis of the jaws. Austr. Dent. J. (2003) 48(4):268.
   PubMedGoogle Scholar
• MARX RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral. Maxillofac. Surg. (2003) 61:1115-1117.
   PubMed Web of Science ®Google Scholar
• SCHUSTER MW, DYMEK JM: Oral cavity avascular bone necrosis-a newly recognized complication of intravenous (iv) bisphosphonate therapy in cancer patients. Blood (2004) 104:4905.
   Google Scholar
• RUGGIERO SL, MEHROTRA B, ROSENBERG TJ, ENGROFF SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. (2004) 62(5):527-534.
   PubMed Web of Science ®Google Scholar
• MIGLIORATI CA, SIEGEL MA, ELTING LS: Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. (2006) 7(6):508-514.
   PubMed Web of Science ®Google Scholar
• GREENBERG MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2004) 98(3):259-260.
   PubMed Web of Science ®Google Scholar
• ESTILO CL, VAN POZNAK CH, WILLIAMS T et al.: Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: a retrospective study. 2004. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J. Clin. Oncol. (2004) 22(14S):8088.
   Google Scholar
• MIGLIORATI CA, SCHUBERT MM, PETERSON DE, SENEDA LM: Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy. Cancer (2005) 104(1):83-93.
   PubMed Web of Science ®Google Scholar
• GREENBERG MS: Intravenous bisphosphonates and osteonecrosis. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. (2004) 98(3):259-260.
   PubMed Web of Science ®Google Scholar
• SIMS EC, ROGERS PB, BESSER GM, PLOWMAN PN: Severe prolonged hypocalcaemia following pamidronate for malignant hypercalcaemia. Clin. Oncol. (R. Coll. Radiol.) (1998) 10(6):407-409.
   PubMedGoogle Scholar
• PETER R, MISHRA V, FRASER WD: Severe hypocalcaemia after being given intravenous bisphosphonate. Br. Med. J. (2004) 328(7435):335-336.
   PubMed Web of Science ®Google Scholar
• ROSEN CJ, BROWN S: Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N. Engl. J. Med. (2003) 348(15):1503-504.
   PubMed Web of Science ®Google Scholar
• NGUYEN HV, INGRAM KB, BEILIN J: Profound hypocalcaemia after zoledronic acid treatment. Med. J. Austr. (2005) 182(9):494-495.
   PubMedGoogle Scholar
• MISHRA A, WONG L, JONKLAAS J: Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. Endocrine (2001) 14(2):159-164.
   PubMed Web of Science ®Google Scholar
• DURNIAN JM, OLUJOHUNGBE A, KYLE G: Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy. Eye (2005) 19(2):221-222.
   PubMed Web of Science ®Google Scholar
• FRAUNFELDER FW, FRAUNFELDER FT, JENSVOLD B: Scleritis and other ocular side effects associated with pamidronate disodium. Am. J. Ophthalmol. (2003) 135(2):219-222.
   PubMed Web of Science ®Google Scholar
• DE S, MEYER P, CRISP AJ: Pamidronate and uveitis. Br. J. Rheumatol. (1995) 34(5):479.
   PubMedGoogle Scholar
• STEWART GO, STUCKEY BG, WARD LC et al.: Iritis following intravenous pamidronate. Aust. NZ. J. Med. (1996) 26(3):414-415.
   PubMedGoogle Scholar
• MACAROL V, FRAUNFELDER FT: Pamidronate disodium and possible ocular adverse drug reactions. Am. J. Ophthalmol. (1994) 118(2):220-224.
   PubMed Web of Science ®Google Scholar
• SUBRAMANIAN PS, KERRISON JB, CALVERT PC, MILLER NR: Orbital inflammatory disease after pamidronate treatment for metastatic prostate cancer. Arch. Ophthalmol. (2003) 121(9):1335-1336.
   PubMed Web of Science ®Google Scholar
• TANVETYANON T, STIFF PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. (2006) 17:897-907.
   PubMed Web of Science ®Google Scholar
• BRUFSKY A: Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin. Oncol. (2006) 33(2 Suppl. 7):S13-S17.
   Google Scholar
• LIPTON A: Toward new horizons: the future of bisphosphonate therapy. Oncologist (2004) 9(Suppl. 4):38-47.
   PubMed Web of Science ®Google Scholar
• CLEZARDIN P: The antitumor potential of bisphosphonates. Semin. Oncol. (2002) 29(Suppl. 21):33-42.
   PubMed Web of Science ®Google Scholar